Skip to content
Addressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship: An Integrative Approach
Upper GI Cancer: Esophageal and Gastric-New Developments
Pancreas, Hepatic and Cholangiocarcinoma: Advances in 2024
Colorectal Cancer: Novel Treatment Paradigms
Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor)
Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against)
Melanoma: Novel Advances in Immunotherapy
Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies
End of Life Management: Oncologists’ Perspectives
Lifestyle Modifications in Reducing Risk of Recurrence
Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts
Soft Tissue and Osteosarcomas: Novel Advances in 2024
Novel Advances for Thyroid Carcinoma and Thymoma
Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer
New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)
ctDNA in Lung Cancer: Current State and Future Perspectives
Challenges in Lung Cancer Pathology: Biomarkers
Screening in Lung Cancer: Challenges and Obstacles
Optimal Surgical Approach in Early Stages NSCLC
Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
What Is Next After Osimertinib Progression?
Post navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok 
